纳米线检测尿液HPV DNA用于宫颈癌筛查的临床表现评估
本研究纳入67例有Cobas HPV检测结果的女性(HPV阳性42例、阴性25例),配对提供宫颈与尿液样本,用聚乙烯亚胺偶联纳米线(PEI-NWs)检测尿液HPV DNA并与宫颈样本比较基因型一致性。结果显示配对尿液与宫颈样本高危HPV(hrHPV)一致率为90.4%(κ=0.90;95%CI:0.80-100.00),200 μL小体积尿液对HPV16、HPV18及其他hrHPV均有较高敏感性(81.3%、100.0%、96.4%)和特异性(98.0%、95.3%、100.0%),提示尿液HPV DNA可作为一种替代生物标志物。
要点
- 配对尿液与宫颈样本hrHPV一致率达90.4%,κ=0.90
- 200 μL尿液即可检测,HPV16敏感性81.3%、特异性98.0%
- HPV18与其他hrHPV的敏感性分别为100.0%和96.4%
核心结论
- 纳米线检测法能很好地从尿液标本中识别HPV DNA,配对尿液与宫颈样本的高危HPV检测一致性极佳,即使尿液样本体积很小。
研究设计与样本
- 在有Cobas HPV检测结果的患者中纳入67例女性(HPV阳性42例、阴性25例),配对提供宫颈和尿液样本,用纳米线检测法比较两种样本HPV基因型的一致性。
主要发现
- 配对尿液与宫颈样本高危HPV一致率为90.4%(κ=0.90;95%CI:0.80-100.00);200 μL尿液检测HPV16组敏感性81.3%(κ=0.83;95%CI:62.1-100.0)、特异性98.0%(κ=0.83;95%CI:94.2-100.0);HPV18组敏感性100.0%(κ=0.65;95%CI:100.0-100.0)、特异性95.3%(κ=0.65;95%CI:90.1-100.0);其他hrHPV组敏感性96.4%(κ=0.97;95%CI:89.6-100.0)、特异性100.0%(κ=0.97;95%CI:100.0-100.0)。
临床怎么用
- 尿液HPV DNA检测有望作为HPV初筛的替代生物标志物用于宫颈癌筛查,样本量小、采集无创。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether HPV DNA in urine has potential advantages as an alternative biomarker for HPV-based cervical cancer screening. METHODS: Among patients with Cobas HPV test results, a total of 67 HPV-positive (n = 42) and -negative (n = 25) women who agreed to participate in this study were willing to provide paired cervical and urine samples, and we observed concordance between sample types from each patient in identifying HPV genotypes using the nanowire assay. RESULTS: We detected high-risk strains of HPV DNA in unprocessed urine specimens using polyethyleneimine-conjugated nanowires (PEI-NWs). Concordance for high-risk HPV (hrHPV) between paired urine and cervical samples was 90.4% (κ = 0.90; 95% CI: 0.80-100.00). The virological sensitivity and specificity for detection of HPV DNA from a small urine sample (200 μL) were 81.3% (κ = 0.83; 95% CI: 62.1-100.0) and 98.0% (κ = 0.83; 95% CI: 94.2-100.0) for HPV16 group, 100.0% (κ = 0.65; 95% CI: 100.0-100.0) and 95.3% (κ = 0.65; 95% CI: 90.1-100.0) for HPV18 group, and 96.4% (κ = 0.97; 95% CI: 89.6-100.0) and 100.0% (κ = 0.97; 95% CI: 100.0-100.0) for other hrHPV group, respectively. CONCLUSIONS: The nanowire assay demonstrated excellent ability to identify HPV DNA from urine specimens. We observed an excellent agreement in the detection of high-risk HPV between paired urine and cervical samples, even with small urine sample volume.
引用
- Lee H, Choi M, Jo M, et al. Assessment of clinical performance of an ultrasensitive nanowire assay for detecting human papillomavirus DNA in urine. Gynecol Oncol. 2020. PMID: 31926639. doi:10.1016/j.ygyno.2019.11.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。